Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF

Stock Information for Tenax Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Tenax Therapeutics Inc.

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Tenax Therapeutics Announces $25 Million Private Placement
Tenax Therapeutics to Participate in the Guggenheim SMID Cap Biotech Conference
Tenax Therapeutics Appoints Gillian Andor Vice President, Clinical Operations
Tenax Therapeutics Reports Third Quarter 2024 Financial Results and Provides a Corporate Update
Tenax Therapeutics to Present at the Guggenheim Healthcare Innovation Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.